National strategy planned to tackle liver disease

pharmafile | October 22, 2009 | News story | |  NHS 

A 'liver czar' is to be brought into the Department of Health to develop and oversee an effective strategy to combat liver disease.

The recruitment process for the new national clinical director has not yet started, but they are expected to be in post "in the next few months", the government said.

The disease currently costs the NHS £460 million a year and health minister Ann Keen said it was affecting people at an increasingly young age.

The new appointee "will ensure that clinical evidence and outcomes for patients are at the heart of our work to improve the quality of services to tackle liver disease", she added.

The government believes identifying people earlier and encouraging them to modify their behaviour are crucial if the rise in cases is to be stopped.

Liver disease is largely preventable and can be treated if diagnosed sufficiently early, but getting the right services in place will also be key.

Although it can be caused by viral hepatitis, excessive iron and some rare disorders, the most common causes of liver disease are lifestyle factors – heavy drinking and obesity.

Managing obesity is already the focus of two recent Department of Health campaigns, Know Your Limits and Change4Life, part of a £372m investment to tackle the issue.

Non Alcoholic Fatty Liver Disease (NAFLD) is a growing concern amongst liver specialists, the government warns.

Currently the fifth most common cause of death in England, liver disease could overtake stroke and coronary heart disease as a killer in the next two decades, the government says.

The British Association for the Study of the Liver (BASL) welcomed the announcement of a national strategy.

The organisation's secretary Rajiv Jalan said: "We hope that its implementation will help to stem the rising burden of liver disease in the UK."

BASL is keen to feed through findings from its own recent report, A Time To Act: Improving liver health and outcomes in liver disease, which it produced with the British Society for Gastroenterology Liver Section.

"We believe these recommendations will provide a solid foundation for the national liver strategy," said Jalan.

The average age of death from liver disease is 59, compared to 82 for heart disease and 84 for stroke.

a2a_linkname=”Pharmafocus”;a2a_linkurl=”http://www.pharmafocus.com”;a2a_num_services=6;a2a_prioritize=[”twitter”,”linkedin”,”facebook”,”delicious”,”friendfeed”,”stumbleupon”,”reddit”];

Related Content

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis

Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence …

Latest content